NP118809

• CAT Number: I003499
• CAS Number: 41332-24-5
• Molecular Formula: C32H32N2O
• Molecular Weight: 460.61
• Purity: ≥95%
• Synonyms: 1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one
• Target: Neuronal Signaling
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IC50: 0.11 uM (for N-type Calcium channel)
• InChI: InChI=1S/C32H32N2O/c35-31(25-30(26-13-5-1-6-14-26)27-15-7-2-8-16-27)33-21-23-34(24-22-33)32(28-17-9-3-10-18-28)29-19-11-4-12-20-29/h1-20,30,32H,21-25H2
• InChIKey: VCPMZDWBEWTGNW-UHFFFAOYSA-N
• SMILES: C1CN(CCN1C(C2=CC=CC=C2)C3=CC=CC=C3)C(=O)CC(C4=CC=CC=C4)C5=CC=CC=C5

NP118809（Cat No.:I003499）is an investigational small molecule being studied for its potential as a therapeutic agent in cancer treatment. It functions as an inhibitor of the bromodomain and extraterminal (BET) family of proteins, particularly targeting BRD4, which plays a crucial role in regulating gene expression and promoting tumor cell growth. By inhibiting BRD4, NP118809 aims to block oncogenic transcriptional programs, thereby slowing or halting cancer progression. Preclinical studies suggest its potential efficacy in various cancers, including hematological malignancies and solid tumors. Further clinical trials are needed to evaluate its safety, pharmacodynamics, and therapeutic potential.

Reference

[1]. Zamponi GW, et al. Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6467-72.
[2]. Pajouhesh H, et al. Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors. Bioorg Med Chem Lett. 2010 Feb 15;20(4):1378-83.